Liminatus Pharma Stock Forward View - Simple Regression
| LIMN Stock | 0.59 0.0005 0.08% |
Liminatus Stock outlook is based on your current time horizon. Although Liminatus Pharma's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Liminatus Pharma's systematic risk associated with finding meaningful patterns of Liminatus Pharma fundamentals over time.
As of today, the RSI of Liminatus Pharma's share price is approaching 37. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Liminatus Pharma, making its price go up or down. Momentum 37
Sell Extended
Oversold | Overbought |
Using Liminatus Pharma hype-based prediction, you can estimate the value of Liminatus Pharma Class from the perspective of Liminatus Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Regression forecasted value of Liminatus Pharma Class on the next trading day is expected to be 0.57 with a mean absolute deviation of 0.08 and the sum of the absolute errors of 4.85. Liminatus Pharma after-hype prediction price | USD 0.58 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Liminatus | Build AI portfolio with Liminatus Stock |
Liminatus Pharma Additional Predictive Modules
Most predictive techniques to examine Liminatus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Liminatus using various technical indicators. When you analyze Liminatus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Liminatus Pharma Simple Regression Price Forecast For the 31st of January
Given 90 days horizon, the Simple Regression forecasted value of Liminatus Pharma Class on the next trading day is expected to be 0.57 with a mean absolute deviation of 0.08, mean absolute percentage error of 0.01, and the sum of the absolute errors of 4.85.Please note that although there have been many attempts to predict Liminatus Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Liminatus Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Liminatus Pharma Stock Forecast Pattern
| Backtest Liminatus Pharma | Liminatus Pharma Price Prediction | Buy or Sell Advice |
Liminatus Pharma Forecasted Value
In the context of forecasting Liminatus Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Liminatus Pharma's downside and upside margins for the forecasting period are 0.01 and 9.26, respectively. We have considered Liminatus Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Liminatus Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Liminatus Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.4725 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0795 |
| MAPE | Mean absolute percentage error | 0.0967 |
| SAE | Sum of the absolute errors | 4.8504 |
Predictive Modules for Liminatus Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Liminatus Pharma Class. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Liminatus Pharma After-Hype Price Density Analysis
As far as predicting the price of Liminatus Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Liminatus Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Liminatus Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Liminatus Pharma Estimiated After-Hype Price Volatility
In the context of predicting Liminatus Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Liminatus Pharma's historical news coverage. Liminatus Pharma's after-hype downside and upside margins for the prediction period are 0.03 and 9.27, respectively. We have considered Liminatus Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Liminatus Pharma is out of control at this time. Analysis and calculation of next after-hype price of Liminatus Pharma Class is based on 3 months time horizon.
Liminatus Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Liminatus Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Liminatus Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Liminatus Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.95 | 8.69 | 0.01 | 0.04 | 5 Events / Month | 8 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.59 | 0.58 | 1.61 |
|
Liminatus Pharma Hype Timeline
Liminatus Pharma Class is now traded for 0.59. The entity has historical hype elasticity of -0.01, and average elasticity to hype of competition of -0.04. Liminatus is expected to decline in value after the next headline, with the price expected to drop to 0.58. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -1.61%, whereas the daily expected return is now at -0.95%. The volatility of related hype on Liminatus Pharma is about 23486.49%, with the expected price after the next announcement by competition of 0.55. About 83.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.16. Liminatus Pharma Class had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 5 days. Check out Historical Fundamental Analysis of Liminatus Pharma to cross-verify your projections.Liminatus Pharma Related Hype Analysis
Having access to credible news sources related to Liminatus Pharma's direct competition is more important than ever and may enhance your ability to predict Liminatus Pharma's future price movements. Getting to know how Liminatus Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Liminatus Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ATHE | Alterity Therapeutics | 0.05 | 6 per month | 0.00 | (0.12) | 5.71 | (8.48) | 17.55 | |
| NNVC | NanoViricides | (0.14) | 37 per month | 0.00 | (0.08) | 9.91 | (8.60) | 34.35 | |
| GBIO | Generation Bio Co | (0.06) | 10 per month | 0.00 | (0.07) | 3.39 | (3.99) | 12.30 | |
| MURA | Mural Oncology Plc | (0.07) | 15 per month | 0.00 | (0.12) | 0.96 | (0.48) | 4.78 | |
| EVAX | Evaxion Biotech AS | 0.46 | 7 per month | 0.00 | (0.12) | 9.15 | (10.68) | 37.88 | |
| BTAI | BioXcel Therapeutics | (0.02) | 11 per month | 0.00 | (0.09) | 8.90 | (7.32) | 22.33 | |
| JSPR | Jasper Therapeutics | (0.56) | 11 per month | 0.00 | (0.1) | 7.73 | (9.04) | 31.75 | |
| DYAI | Dyadic International | (0.07) | 10 per month | 0.00 | (0.09) | 6.82 | (6.32) | 16.34 | |
| SABS | SAB Biotherapeutics | (0.03) | 7 per month | 2.97 | 0.15 | 7.97 | (4.05) | 22.52 | |
| MAIA | MAIA Biotechnology | 0.07 | 11 per month | 6.26 | 0.13 | 12.60 | (8.89) | 35.91 |
Other Forecasting Options for Liminatus Pharma
For every potential investor in Liminatus, whether a beginner or expert, Liminatus Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Liminatus Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Liminatus. Basic forecasting techniques help filter out the noise by identifying Liminatus Pharma's price trends.Liminatus Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Liminatus Pharma stock to make a market-neutral strategy. Peer analysis of Liminatus Pharma could also be used in its relative valuation, which is a method of valuing Liminatus Pharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Liminatus Pharma Market Strength Events
Market strength indicators help investors to evaluate how Liminatus Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Liminatus Pharma shares will generate the highest return on investment. By undertsting and applying Liminatus Pharma stock market strength indicators, traders can identify Liminatus Pharma Class entry and exit signals to maximize returns.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.59 | |||
| Day Typical Price | 0.59 | |||
| Price Action Indicator | (0.0008) | |||
| Period Momentum Indicator | (0.0005) | |||
| Relative Strength Index | 37.31 |
Liminatus Pharma Risk Indicators
The analysis of Liminatus Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Liminatus Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting liminatus stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.36 | |||
| Standard Deviation | 8.5 | |||
| Variance | 72.31 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Liminatus Pharma
The number of cover stories for Liminatus Pharma depends on current market conditions and Liminatus Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Liminatus Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Liminatus Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Liminatus Pharma Short Properties
Liminatus Pharma's future price predictability will typically decrease when Liminatus Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Liminatus Pharma Class often depends not only on the future outlook of the potential Liminatus Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Liminatus Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.2 M | |
| Cash And Short Term Investments | 804.5 K | |
| Shares Float | 4.5 M |
Check out Historical Fundamental Analysis of Liminatus Pharma to cross-verify your projections. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Will Biotechnology sector continue expanding? Could Liminatus diversify its offerings? Factors like these will boost the valuation of Liminatus Pharma. Expected growth trajectory for Liminatus significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Liminatus Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.16) |
Liminatus Pharma Class's market price often diverges from its book value, the accounting figure shown on Liminatus's balance sheet. Smart investors calculate Liminatus Pharma's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Liminatus Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Liminatus Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Liminatus Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Liminatus Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.